Meropenem pharmacokinetics in children and adolescents receiving hemodialysis

Area of Science:

• Pharmacology
• Nephrology
• Pediatrics

Background:

• Multi-drug-resistant bacteria pose a significant threat to pediatric patients with end-stage renal disease (ESRD).
• Gram-negative infections, particularly Pseudomonas aeruginosa, are challenging to treat in ESRD patients on dialysis and may require catheter removal.
• Meropenem is a broad-spectrum carbapenem antibiotic with activity against P. aeruginosa.

Purpose of the Study:

• To evaluate the pharmacokinetics of meropenem in pediatric patients undergoing hemodialysis.
• To determine if the standard meropenem dose provides adequate therapeutic drug concentrations between hemodialysis sessions.

Main Methods:

• Seven pediatric ESRD patients received a single 20 mg/kg dose of meropenem before and after hemodialysis.
• Meropenem concentrations were measured during and between hemodialysis treatments.
• Pharmacokinetic parameters, including drug half-life and clearance, were analyzed.
• Dosing simulations were performed to identify optimal dosing regimens.

Main Results:

• Meropenem administration was well-tolerated with no adverse effects.
• Hemodialysis effectively cleared meropenem, correlating with urea reduction.
• The median drug half-life off dialysis was 7.3 hours.
• The 20 mg/kg dose was insufficient to maintain meropenem concentrations above the MIC90 for P. aeruginosa for 70% of the interdialytic interval.

Conclusions:

• The standard meropenem dose of 20 mg/kg is inadequate for pediatric ESRD patients on hemodialysis.
• Simulations suggest daily 25 mg/kg or alternate-day 40 mg/kg doses would achieve acceptable pharmacodynamic profiles.
• Optimized meropenem dosing is crucial for effective treatment of infections in this vulnerable population.